Sun Pharma`s Ilumya (Tildrakizumab asmn) Receives Suppl Approval in the U.S.
Sun Pharma specialty drug Tildrakizumab makes it to China's reimbursement list
Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis
Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis
Sun Pharmaceutical Industries announced that the New Drug Application (NDA) for tildrakizumab injection under the brand name ILUMETRI has been approved by the National Medical Products Administration of the People’s Republic of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In June 2019, Sun Pharma out-licensed tildrakizumab to a subsidiary of China Medical System Holdings Limited (CMS), for development, regulatory filings and commercialisation of the product in Greater China. According to CMS, the results of the extended study of Phase III clinical trial in China demonstrated that the primary efficacy assessment indicator PASI 75 response rate continued to increase over the treatment time. The PASI 75 response rate reached a high level after 28 weeks of treatment with ILUMETRI and maintained at 91.3 per cent at week 52, and ILUMETRI showed good long-term safety and tolerance.
Sun' Biologic Ilumya (Tildrakizumab) Receives Approval in the U.S.
PRINCETON, N.J., March 24, 2022 /PRNewswire/ -- Sun Pharmaceutical Industries Inc., USA (Sun Pharma) today announced that five data abstracts for ILUMYA® (tildrakizumab-asmn) in patients with moderate-to-severe plaque psoriasis will be presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting, taking place March 25-29. The data to be highlighted shows ILUMYA treatment in patients with moderate-to-severe plaque psoriasis in real-world practice resulted in significant improvement from baseline disease activity and baseline quality of life with no new safety concerns.
Sun Pharma’s latest ad campaign opens in a Savannah, Georgia, diner. Four psoriasis patients on its treatment Ilumya meet for the first time to share coffee and similar stories.